Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Analysis and Forecast

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Transformative Dynamics and Opportunities 

The Histone Deacetylase 6, Pipeline (Drugs Under Development), Market has been witnessing profound transformation driven by targeted oncology research and a surge in precision medicine approaches. As indicated by Datavagyanik, the demand for highly selective histone deacetylase 6 (HDAC6) inhibitors has accelerated, propelled by their unique role in regulating non-histone proteins implicated in various cancers. For instance, clinical-stage molecules targeting HDAC6 show significant promise in hematological malignancies and solid tumors, which is propelling substantial investments in this pipeline. According to Datavagyanik, the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Size is forecasted to expand robustly as a result of these innovations, with emerging molecules advancing into mid- and late-stage trials. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Strategic Shift in Oncology Research 

The Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is gaining traction as pharmaceutical research pivots toward epigenetic modulators. Histone deacetylase 6, unlike class I HDACs, controls processes including protein degradation, autophagy, and intracellular transport, making it a unique therapeutic target. Datavagyanik highlights that this strategic shift is motivated by the growing incidence of cancers involving abnormal protein aggregation and microtubule instability. For example, approximately 1.9 million new cancer cases were diagnosed in the United States in 2023 alone, creating a fertile landscape for HDAC6-targeted therapeutics to gain clinical momentum. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Rising Investments and Competitive Dynamics 

The competitive dynamics within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market are being reshaped by a surge in investment from large pharmaceutical players and biotechnology firms. Datavagyanik notes that venture funding in oncology therapeutics crossed $11 billion in 2023, with a noticeable share directed toward HDAC6 programs. For instance, emerging biotechs are collaborating with academic research centers to accelerate candidate development, driving a more collaborative ecosystem. This trend is expected to stimulate first-in-class and best-in-class molecules with differentiated safety profiles, expanding the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market in the near future. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Expanding Application Areas 

Datavagyanik emphasizes that the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is benefitting from expanding application areas beyond oncology. Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are emerging as critical targets for HDAC6 inhibitors because of their ability to modulate protein misfolding and aggregation. For instance, it is estimated that more than 55 million people are living with dementia worldwide, a number expected to double by 2050, strengthening the relevance of HDAC6-targeted therapeutics. Consequently, the pipeline for these agents is diversifying, positioning the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market for sustainable long-term growth. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Influence of Biomarker Strategies 

The integration of biomarker-driven strategies is another powerful driver in the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. By leveraging genomic and proteomic data, developers can better stratify patient populations and predict response to HDAC6 inhibitors. For instance, Datavagyanik highlights that companion diagnostics and biomarker validation programs are reducing attrition rates in clinical development. Such precision-based approaches have been shown to improve response rates in oncology trials by up to 30%, which is anticipated to accelerate regulatory approvals and strengthen the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Size over the forecast period. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Role of Combination Therapies 

Datavagyanik suggests that the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is being increasingly shaped by combination therapy strategies. For example, pairing HDAC6 inhibitors with checkpoint inhibitors or proteasome inhibitors has yielded promising synergistic effects in early-phase trials. In one study, combination regimens demonstrated tumor response rates exceeding 40% in relapsed or refractory lymphoma, compared with single-agent responses below 20%. These results are encouraging developers to invest in novel combination pipelines, which is anticipated to create significant differentiation in the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market landscape. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Regulatory Landscape Advancements 

The regulatory environment surrounding the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market has evolved to support fast-track designations and breakthrough therapy status for innovative assets. Datavagyanik observes that expedited pathways have reduced development timelines by 25–30% in oncology indications. Such regulatory incentives are motivating sponsors to pursue more aggressive development strategies, ensuring a robust influx of new assets into the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. This is expected to translate into a broader commercial opportunity in the coming five years. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Technological Innovations 

Datavagyanik points out that the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is increasingly benefiting from advanced molecular modeling and AI-driven drug discovery. Artificial intelligence platforms are accelerating target validation and lead optimization for HDAC6 inhibitors, with some platforms reducing discovery timelines by as much as 40%. For instance, machine learning tools have already identified novel binding pockets in the HDAC6 catalytic domain, paving the way for more selective and potent drug candidates. This technological shift is reinforcing the innovation pipeline and strengthening the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market outlook. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Opportunities in Rare Diseases 

A compelling growth driver within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is the exploration of rare disease indications. Datavagyanik highlights that rare proteinopathies and inherited neurodegenerative conditions are underexplored territories where HDAC6 inhibition could provide meaningful disease modification. For example, there are over 7,000 rare diseases globally, affecting more than 300 million individuals, yet less than 5% of these conditions have approved treatments. This significant unmet need creates an opportunity for the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market to deliver high-value orphan drug candidates. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Future Market Size and Revenue Potential 

Datavagyanik underscores that the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Size is poised for substantial growth, driven by diverse indications, supportive regulation, and high innovation momentum. Analysts expect mid-single-digit compound annual growth rates for the overall HDAC inhibitors market, with HDAC6-specific drugs capturing a progressively larger share. For instance, commercial opportunities for HDAC6 inhibitors in oncology alone could exceed $2 billion annually by the end of this decade, further underlining the commercial viability of these programs within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Conclusion and Forward View 

In conclusion, the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is at a pivotal inflection point, marked by scientific breakthroughs, regulatory tailwinds, and robust funding. As Datavagyanik indicates, the growing integration of precision biomarkers, combination strategies, and advanced drug discovery techniques will continue to propel this market forward. The Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is well positioned to unlock value across oncology, neurodegeneration, and rare diseases, shaping a transformative future in epigenetic drug development. Stakeholders in this segment are anticipated to benefit from a wave of first- and best-in-class therapeutics that address critical gaps in the current treatment landscape, thereby expanding the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Size to new horizons. 

 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Regional Growth Patterns and Global Shifts 

Datavagyanik observes that the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is experiencing highly differentiated geographical growth patterns. North America is projected to hold a commanding share, supported by a concentration of oncology research centers and high patient enrollment rates for hematological malignancies. For instance, the United States is home to more than 40% of global oncology clinical trials, giving it an outsized influence on early-stage and late-stage HDAC6 programs. The Histone Deacetylase 6, Pipeline (Drugs Under Development), demand in this region is further boosted by an advanced regulatory framework enabling fast-track approvals, which shortens the time to market for promising assets. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Rising European Investments 

In Europe, the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is advancing on the back of collaborative academic networks and publicly funded cancer research initiatives. Datavagyanik highlights that countries such as Germany, France, and the United Kingdom are prioritizing precision oncology pipelines with a strong emphasis on rare cancers. For example, the European Union’s “Mission on Cancer” initiative has allocated over €4 billion through 2030 to support translational cancer research. Such funding is fueling Histone Deacetylase 6, Pipeline (Drugs Under Development), demand, positioning Europe as a major hub for second-generation HDAC6 inhibitor development. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Asia-Pacific Emergence 

Datavagyanik underlines that the Asia-Pacific region is emerging as a vital frontier for the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. Japan and South Korea, for instance, have demonstrated exceptional growth in molecular oncology pipelines, supported by government-backed incentives for rare disease programs. In addition, China is rapidly expanding its clinical trial infrastructure, having registered a 15% annual growth rate in oncology-related investigational new drug filings over the past three years. Such momentum is expected to drive significant Histone Deacetylase 6, Pipeline (Drugs Under Development), demand as local biopharma players increasingly license-in HDAC6 candidates to accelerate domestic development. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Growth in Emerging Regions 

The Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is also seeing gradual traction in Latin America and parts of the Middle East. Datavagyanik notes that as cancer incidence rates climb in these emerging regions, the unmet clinical needs are drawing the attention of multinational pharmaceutical companies. For example, Latin America’s cancer burden is projected to exceed 2.4 million new cases annually by 2030, creating demand for advanced epigenetic therapies. This is encouraging local partnerships and knowledge transfer programs, strengthening the future pipeline for Histone Deacetylase 6, Pipeline (Drugs Under Development), Market players in these geographies. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Segmentation by Indication 

Datavagyanik points out that the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is segmented heavily by therapeutic indication. Oncology continues to represent the dominant segment, accounting for more than 75% of the pipeline activity, particularly in hematological malignancies and solid tumors such as multiple myeloma, lymphoma, and ovarian cancer. For instance, there are more than 1.2 million new lymphoma cases diagnosed globally each year, making it a high-priority area for HDAC6 inhibitor development. Beyond cancer, neurodegenerative conditions represent another fast-growing segment, with trials investigating HDAC6 inhibition in Alzheimer’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease. Datavagyanik expects this segmentation to diversify further as clinical evidence matures. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Segmentation by Drug Class 

Within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market, segmentation by drug class is evolving rapidly. Selective HDAC6 inhibitors now comprise a growing proportion of investigational agents, representing a departure from traditional pan-HDAC inhibitors, which were associated with higher toxicity. Datavagyanik highlights that more than 60% of new molecules in the pipeline are selective HDAC6 inhibitors, aimed at improving tolerability and target specificity. For example, emerging compounds have shown up to 40% fewer grade 3/4 adverse events compared with pan-HDAC inhibitors, supporting their advancement into later-phase trials and contributing to Histone Deacetylase 6, Pipeline (Drugs Under Development), demand among clinical investigators. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Segmentation by Route of Administration 

Datavagyanik identifies the route of administration as another important segmentation factor in the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. Oral formulations dominate the pipeline landscape because of superior patient compliance and the growing trend of home-based cancer treatment regimens. For example, oral therapies now represent approximately 65% of oncology drugs under clinical development globally, a trend reflected in HDAC6 inhibitor programs as well. Parenteral formulations continue to have a place, particularly in acute hospital settings, but the convenience of oral dosing is driving clear preference and influencing the direction of clinical research investment in the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Pricing Dynamics and Cost Drivers 

Datavagyanik suggests that pricing trends within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market will be shaped by the cost of precision biomarker development, companion diagnostics, and advanced manufacturing technologies. For instance, the use of complex biologic assays to stratify patients adds around 10–15% to the cost of drug development, translating into higher launch prices. Early estimates place the average annual treatment cost of future HDAC6 inhibitors between $90,000 and $150,000 per patient, depending on indication and biomarker inclusion. Such pricing is justified by high clinical unmet need and by the demonstrated capacity of HDAC6 inhibitors to prolong survival in patients with limited options, further reinforcing Histone Deacetylase 6, Pipeline (Drugs Under Development), demand in high-income markets. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Reimbursement and Access Considerations 

Datavagyanik notes that payers will play a critical role in determining market access within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. For example, oncology drugs in the United States face an average time-to-reimbursement of eight to ten months post-approval, while Europe typically requires 12–18 months for full health technology assessment reviews. As HDAC6 inhibitors demonstrate robust data in biomarker-validated subgroups, their reimbursement prospects will strengthen, reducing patient out-of-pocket expenses and broadening their adoption. This dynamic is essential to sustaining Histone Deacetylase 6, Pipeline (Drugs Under Development), demand and accelerating revenue ramp-up for market entrants. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Competitive Pricing Outlook 

Within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market, Datavagyanik anticipates competitive pricing pressures to intensify as multiple assets approach commercialization. For instance, the presence of several mid-stage selective HDAC6 inhibitors, each vying for similar patient populations, could create downward pricing pressure to secure formulary positions. Volume-based contracts and outcomes-based pricing models may emerge as dominant reimbursement strategies to align stakeholder incentives. Such shifts are likely to drive sustainable access while ensuring Histone Deacetylase 6, Pipeline (Drugs Under Development), demand is supported across different geographies and payer segments. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Price Sensitivity in Emerging Markets 

Datavagyanik highlights that emerging economies will display heightened price sensitivity within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. For example, per capita cancer care spending in India and Brazil remains under $200 compared to over $3,000 in the United States. This financial gap will influence pricing strategies, with local partnerships and tiered pricing models becoming crucial for penetration. Pharmaceutical players must balance profitability with equitable access to ensure that Histone Deacetylase 6, Pipeline (Drugs Under Development), demand in these markets can be sustainably cultivated without exacerbating healthcare inequalities. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Future Segmentation Evolution 

Datavagyanik anticipates future segmentation within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market to evolve around combination product approvals, pediatric trials, and expansion to rare neurological indications. For instance, the orphan disease market is projected to grow at an 11% CAGR through 2030, creating compelling opportunities for HDAC6 inhibitors to be repurposed beyond oncology. In addition, the inclusion of pediatric studies could open new patient pools, supported by regulatory frameworks that increasingly encourage pediatric investigation plans. This evolution will stimulate Histone Deacetylase 6, Pipeline (Drugs Under Development), demand in specialized treatment areas and broaden the overall patient access landscape. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market: Conclusion on Price and Demand Outlook 

In closing, Datavagyanik concludes that the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is being decisively shaped by regional oncology infrastructure, precision biomarker innovation, and new pricing paradigms. The Histone Deacetylase 6, Pipeline (Drugs Under Development), demand is expected to grow steadily across high-income countries, while emerging markets will require adaptive pricing models to expand access. Segmentation trends are becoming more nuanced, and the pipeline is steadily diversifying across indications, routes of administration, and targeted subgroups. Stakeholders positioning themselves early in these growth geographies and anticipating reimbursement hurdles will be best equipped to capitalize on the long-term expansion of the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. 

 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Players: Competitive Landscape Overview 

Datavagyanik assesses that the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is driven by a set of prominent pharmaceutical innovators and specialized biotechnology firms. These market players are actively pursuing highly selective HDAC6 inhibitors to differentiate their portfolios from legacy pan-HDAC assets. Among the recognized leaders, Acetylon Pharmaceuticals, a part of Celgene, has been developing ricolinostat, a selective HDAC6 inhibitor positioned for hematological malignancies. This molecule is currently progressing through advanced clinical stages and has been observed to achieve promising tolerability in patients with multiple myeloma, enhancing its prospects for market share capture within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Players: Emerging Biotech Innovators 

Another relevant stakeholder is C4 Therapeutics, which has been exploring CFT7455, a targeted protein degrader with strong selectivity for HDAC6, using their proprietary degrader platform. Datavagyanik identifies this asset as a potentially disruptive player because it combines the catalytic inhibition of HDAC6 with proteasomal degradation, addressing multiple mechanistic pathways involved in tumor proliferation. This hybrid modality is giving C4 Therapeutics a unique competitive advantage in the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market, which could translate to future first-in-class product opportunities. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Players: Large Pharmaceutical Firms 

Datavagyanik highlights Pfizer as another significant participant in the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market, given its advanced research portfolio in hematology and solid tumor therapies. Pfizer has been exploring selective HDAC6 inhibition as a complementary strategy to its immunotherapy assets, such as the PD-L1 inhibitor avelumab. By integrating these therapeutic platforms, Pfizer aims to develop robust combination regimens that could command higher market share in oncology-driven indications, particularly where immunotherapy alone has not achieved sufficient durable responses. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Players: Mid-Sized Companies Gaining Traction 

Datavagyanik also notes the rising presence of Syndax Pharmaceuticals, which has developed entinostat, primarily a class I HDAC inhibitor but with increasing interest toward HDAC6 co-targeting strategies. Syndax is currently exploring combination pathways to integrate HDAC6 modulators into its treatment backbone, giving it a future stake in the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. These mid-sized companies are leveraging nimble R&D models to compete effectively with larger multinationals, enabling them to move assets rapidly through clinical trials and position for commercial partnerships. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Players: Pipeline Diversity 

Datavagyanik states that the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is distinguished by its diversity of approaches. For example, Vivace Therapeutics is progressing HDAC6 modulators with proprietary oral formulations targeting breast and ovarian cancer. Vivace’s program uses unique molecular scaffolds designed to reduce off-target toxicity, which historically limited the clinical success of broad-spectrum HDAC inhibitors. Such differentiated chemistry is anticipated to improve adoption rates once the product reaches the market, strengthening Vivace’s competitive positioning in the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Players: Market Share Trends 

In terms of estimated market share, Datavagyanik suggests that Celgene (under Bristol Myers Squibb), owing to its investment in ricolinostat and related programs, is positioned to capture a leading share of approximately 25–30% once commercialization proceeds. C4 Therapeutics could secure between 10–15% share given the promising mechanism of its degrader platform. Mid-sized firms such as Syndax and Vivace Therapeutics may achieve between 5–10% depending on partnership agreements and speed of regulatory filings. The remainder of the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is expected to be divided among emerging biotech entrants and academic collaborations, many of which are still in preclinical or phase I stages. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Players: Synergistic Partnerships 

Datavagyanik underscores the importance of partnership models in this pipeline. For instance, alliances between academic medical centers and biotech firms are expanding early-stage access to patient cohorts, allowing more rapid progression through proof-of-concept studies. These collaborations are especially valuable in rare oncology indications and pediatric populations where recruitment remains challenging. As a result, co-development agreements are forecast to remain an essential competitive pillar for stakeholders seeking share within the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Players: Recent Industry Developments 

Datavagyanik tracks several recent developments relevant to the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market. For instance, in January 2025, C4 Therapeutics announced the advancement of CFT7455 into phase II trials, targeting relapsed/refractory non-Hodgkin lymphoma, which marks a significant milestone in moving beyond early safety evaluation. In March 2025, Vivace Therapeutics disclosed promising phase I results in breast cancer patients, demonstrating early signals of tumor shrinkage, which strengthened investor confidence in its HDAC6 pipeline. 

Furthermore, in May 2025, Syndax Pharmaceuticals confirmed preclinical progress on a new HDAC6-modulating candidate aimed at pediatric sarcomas, scheduled for clinical entry in early 2026. This development highlights the increasing scope of indications pursued under the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market umbrella. Meanwhile, Pfizer reported in April 2025 that it will evaluate its next-generation HDAC6 inhibitors in combination with avelumab across a multicenter phase I/II basket trial, covering both solid tumors and hematologic malignancies. 

Histone Deacetylase 6, Pipeline (Drugs Under Development), Market Players: Strategic Direction 

Datavagyanik concludes that the strategic direction of the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market will remain focused on selective inhibition, combination regimens, and expanded rare disease indications. Players who can build robust biomarker-driven trials and establish early health technology assessment partnerships will be best positioned to maintain or grow market share. As recent examples illustrate, rapid pipeline progress and well-timed collaborations can define success in a highly competitive environment. 

In closing, the Histone Deacetylase 6, Pipeline (Drugs Under Development), Market is anticipated to grow more concentrated over the next five years as phase II and phase III programs mature. However, the influx of novel entrants and breakthrough molecular approaches will keep the competitive landscape dynamic, driving innovation while steadily reshaping patient outcomes across oncology and neurodegenerative diseases alike. 

 

Key Insights that the Histone Deacetylase 6 Market analysis report presents are:

• Break-down of the Histone Deacetylase 6 drugs under development in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Histone Deacetylase 6 Market competitive scenario, market share analysis
• Histone Deacetylase 6 Market business opportunity analysis

Global and Country-Wise Histone Deacetylase 6 Market Statistics

• Global and Country-Wise Histone Deacetylase 6 Market Size ($Million) and Forecast, till 2030
• Global and Country-Wise Histone Deacetylase 6 Market Trend Analysis
• Global and Country-Wise Histone Deacetylase 6 Market Business Opportunity Assessment